Michael Porter’s Five Forces model is a strategic framework used to analyze the global stress urinary incontinence (SUI) market. Strategic decision-makers aiming to gain a competitive advantage can leverage this model to better understand the industry structure, competitive intensity, and profitability dynamics within the urology and women’s health landscape. Each force and its relative impact have been examined in the context of the global SUI market.
PORTER'S FIVE FORCES Analysis: global stress urinary incontinence (SUI) market
Threat of New Entrants
The threat of new entrants is relatively low to moderate, primarily due to stringent regulatory requirements and high development complexity for medical devices. Companies must comply with regulatory standards set by authorities such as the U.S. Food and Drug Administration and the European Union Medical Device Regulation (EU) 2017/745, which require extensive clinical validation, quality system compliance, and post-market surveillance. Additionally, high R&D costs, product liability risks, especially for implantable devices like slings—and the need for strong physician adoption and training limit new market entry. However, growing demand for non-invasive and home-based therapies is creating niche opportunities for innovative entrants.
BARGAINING POWER OF SUPPLIERS
The bargaining power of suppliers in the SUI market is moderate and varies by product type. For absorbent products such as adult diapers and pads, supplier power is relatively low due to the availability of multiple raw material providers and commoditized supply chains. In contrast, for advanced therapeutic devices, such as artificial urinary sphincters, neuromodulation systems, and specialized biomaterial-based slings, supplier power is higher due to reliance on high-quality medical-grade materials, precision components, and specialized contract manufacturers. This creates a differentiated supplier landscape between commodity-based and technologically advanced segments.
Threat of Substitutes
The threat of substitutes is high in the SUI market, driven by the wide availability of non-invasive and low-cost alternatives. Conservative treatments such as pelvic floor muscle training, lifestyle modifications, and behavioral therapies are often the first line of management and can significantly delay or replace the need for medical devices. Additionally, absorbent products provide a convenient and widely accepted solution for symptom management. Emerging digital health tools and non-invasive therapies, including electrical stimulation and laser treatments, further expand the range of substitutes, increasing competitive pressure on traditional interventional devices.
Bargaining Power of Buyers
The bargaining power of buyers, including hospitals, clinics, patients, and public and private payers, is high. Buyers have access to a wide range of treatment options, from low-cost absorbent products to surgical interventions, making them highly price-sensitive. Reimbursement policies and healthcare budget constraints further strengthen buyer influence, particularly in developed markets. Healthcare providers tend to favor clinically proven, cost-effective solutions with established safety profiles, requiring new entrants to demonstrate clear clinical and economic value to achieve adoption and reimbursement approval.
Intensity of Rivalry
The intensity of rivalry in the global SUI market is moderate to high, driven by the presence of established medical device manufacturers and consumer healthcare companies competing across both therapeutic devices and absorbent product segments. While the absorbent products segment is highly competitive and price-driven, the therapeutic devices segment is characterized by innovation-led competition focused on improving efficacy, safety, and patient comfort. Rivalry is further intensifying with the emergence of minimally invasive technologies, digital therapeutics, and home-based treatment solutions. As companies invest in advanced biomaterials, smart devices, and regenerative therapies, the competitive landscape is expected to evolve toward greater differentiation and innovation-driven competition.
Product Pipeline Analysis
Product pipeline
Drug Candidate
Company
Development Stage
Indication/Target
Detail
Flyte System
Pelvital
Commercial / Expansion Phase
Stress Urinary Incontinence (SUI)
Non-invasive pelvic floor muscle stimulation device designed for at-home use; aims to improve muscle strength and reduce leakage episodes without surgery.
Urorelief Device
Relief Srl
Clinical Stage
Stress Urinary Incontinence (SUI)
Endourethral implantable device intended to provide mechanical support to prevent urine leakage; currently undergoing clinical validation.
Leva Pelvic Health System
Axena Health, Inc.
Commercial
Stress Urinary Incontinence (SUI)
FDA-cleared device combined with a mobile app for guided pelvic floor muscle training, offering personalized, at-home therapy with real-time feedback.
Bulkamid Hydrogel
Contura International
Commercial / Post-market Expansion
Stress Urinary Incontinence (SUI)
Injectable urethral bulking agent designed to increase urethral resistance and reduce leakage; minimally invasive alternative to surgery.
UroActive smart implant
UroMems
Clinical Stage
Stress urinary incontinence; smart automated artificial urinary sphincter.
FDA IDE approval and French ANSM clearance in July 2025 enabled the SOPHIA2 pivotal study, and the system is designed to automatically adjust pressure based on patient activity.
SUI-100
Acoustic Wave Cell Therapy, Inc.
Clinical Stage
Mild-to-moderate female stress urinary incontinence.
The device is non-surgical and non-invasive, and the primary objective is at least 50% reduction in urine leakage on the 24-hour pad weight test versus sham.
VMB-100
Versameb AG
Clinical Stage
Stress urinary incontinence; intramuscular locally delivered mRNA encoding human IGF-1 for urinary sphincter muscle regeneration.
Versameb positions VMB-100 as a first-in-class regenerative therapy candidate; the company reports preclinical evidence of urinary sphincter muscle regeneration and functional restoration after a single dose in animal models.
Case Study Analysis
A representative case study from clinical literature provides valuable insights into the real-world diagnosis, treatment pathways, and challenges associated with stress urinary incontinence (SUI), reflecting broader trends in the global SUI market. In one documented case, a 44-year-old woman with a history of childbirth presented with SUI symptoms such as urine leakage during coughing and physical activity, significantly affecting her quality of life and requiring daily use of protective pads. Initial clinical evaluation confirmed moderate urethral hypermobility with no major comorbidities, leading to the adoption of a surgical intervention using a tension-free vaginal tape (TVT-O) procedure. The treatment was initially successful, with the patient experiencing complete symptom relief for approximately one year, highlighting the effectiveness and market relevance of minimally invasive sling procedures as a standard of care.
However, the recurrence of symptoms after three years underscores a critical challenge in the SUI market, long-term durability and recurrence management. Upon re-evaluation, the patient again reported frequent leakage episodes that interfered with daily activities and physical exercise, demonstrating the chronic and recurrent nature of SUI. Clinical discussions around her case revealed that healthcare providers often consider multiple follow-up strategies, including diagnostic reassessment (such as urodynamic testing), pharmacological therapy trials, and repeat surgical interventions.
